Localized Prostate Cancer

Relugolix Plus Radiotherapy for Reduced Castration Rates in Localized Prostate Cancer
The oral gonadotropin-releasing hormone antagonist relugolix was approved in December 2020 for the treatment of localized or advanced prostate cancer (PCa) based on the efficacy seen in the HERO trial, which demonstrated superiority over leuprolide while providing less risk of major cardiovascular events. As androgen deprivation therapy (ADT) paired with radiation is a common treatment for patients with advanced PCa, a recent post hoc analysis examined relugolix in combination with radiotherapy to assess the efficacy and safety of the combination. ...
Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content based on prostate cancer types, therapies, and technologies

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Advertisement
Trending